Contemplating versus having used psychedelics in bipolar disorder - What makes the difference?

Area of Science:

• Psychiatry
• Neuroscience
• Psychopharmacology

Background:

• Psychedelics show promise for mental health treatment.
• Bipolar disorder (BD) patients are often excluded from psychedelic research due to concerns about adverse psychiatric events.
• Understanding the motivations and characteristics of BD individuals considering psychedelics is crucial.

Purpose of the Study:

• To explore the motivations, expectations, and personality traits of individuals with bipolar disorder (BD) who have previously used classic psychedelics (experimenters) versus those considering future use (contemplators).
• To compare experimenters and contemplators on sociodemographic, psychological, and mental health variables.

Main Methods:

• Observational study comparing two groups: individuals with BD who have used psychedelics (experimenters) and those considering using them (contemplators).
• Assessment of sociodemographic, psychological, and mental health variables.
• Comparison of attitudes, motivations, expectations, and personality characteristics between the two groups.

Main Results:

• Experimenters and contemplators did not differ in sociodemographic or mental health variables.
• Experimenters exhibited more positive attitudes towards psychedelics and higher "openness to experience" compared to contemplators.
• Specific motives for psychedelic use were more strongly endorsed by experimenters, while contemplators expressed greater concerns about potential negative effects.

Conclusions:

• Previous psychedelic experience in individuals with bipolar disorder is associated with more positive perceptions and stronger motivations for use.
• Personality traits, particularly "openness to experience," may differentiate those who have used psychedelics from those who are considering them.
• Findings inform discussions regarding psychedelic use in individuals with BD, even within clinical trial contexts, highlighting areas for risk-benefit assessment and patient counseling.